Phase I Evaluation of a Fully Human Anti–αv Integrin Monoclonal Antibody (CNTO 95) in Patients with Advanced Solid Tumors - Concepedia

Concepedia

Publication | Closed Access

Phase I Evaluation of a Fully Human Anti–αv Integrin Monoclonal Antibody (CNTO 95) in Patients with Advanced Solid Tumors

141

Citations

31

References

2007

Year

Saifee Mullamitha, N.C. Ton, Geoff J.M. Parker, Alan Jackson, P. J. Julyan, Caleb Roberts, G. Buonaccorsi, Yvonne Watson, Karen Davies, Sue Cheung,

Clinical Cancer Research

Abstract

CNTO 95 was generally well tolerated. Six patients received extended therapy, including one patient with a prolonged response. Biopsy data confirmed tumor localization and pharmacodynamic activity.

References

	Year	Citations

Page 1